Fig. 2From: Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 studyBest percentage changes from baseline in target lesion size in the efficacy analysis set. CR, complete response; PR, partial response; SD, stable disease; PD, disease progressionBack to article page